Ahmed Almomani, MD
Interventional Cardiology · San Antonio, TXNPI 1225325426
Payments from drug & device makers
Across 280 payments — averaging $291.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$57K
- Boston Scientific$16K
- Medtronic$2K
- Abbott$2K
- Abiomed$1K
- Biotronik Inc.$830
- plus $3K from 23 others
What the payments were for
- Consulting fees$38,31047%
- Speaking & faculty fees$2,1203%
- Grants$15,00018%
- Travel & lodging$12,43615%
- Food & beverage$13,71817%
- Gifts$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 119 | $57,293 |
| Boston Scientific | 10 | $15,589 |
| Medtronic(2 entities) | 22 | $1,874 |
| Abbott | 45 | $1,610 |
| Abiomed | 19 | $1,463 |
| Biotronik Inc. | 19 | $830 |
| Shockwave Medical, Inc | 5 | $589 |
| Heartflow, Inc. | 2 | $273 |
| E.r. Squibb & Sons, L.L.C. | 2 | $246 |
| Teleflex LLC | 3 | $240 |
| Penumbra, Inc. | 2 | $216 |
| Bard Peripheral Vascular, Inc. | 1 | $142 |
| Osprey Medical Inc | 1 | $140 |
| Bayer | 2 | $137 |
| Livanova USA, Inc. | 1 | $135 |
| Acist Medical Systems, Inc. | 3 | $129 |
| Chiesi USA, Inc. | 3 | $122 |
| Inari Medical, Inc. | 2 | $120 |
| Cardiva Medical, Inc. | 1 | $118 |
| Janssen Scientific Affairs, LLC | 1 | $74 |
| Novartis | 3 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $59 |
| Johnson & Johnson | 2 | $48 |
| Angiodynamics, Inc. | 2 | $44 |
| Imperative Care, Inc | 1 | $32 |
| Philips North America LLC | 1 | $22 |
| Getinge USA Sales, LLC | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$47,605
- GENERAL - STRUCTURAL HEART$15,000
- SAPIEN 3 Ultra RESILIA$1,906
- EVOQUE$1,346
- PASCAL$1,336
- CoreValve Evolut$1,191
- Impella$861
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$618
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$287
- FFRct$273
- Vascular Lithotripsy$249
- CAMZYOS$246
- Orsiro Mission$243
- Resolute$142
- VENOVO$142
- DyeVert$140
- DRAGONFLY OPSTAR$137
- Tandem Life Kit$135
- Indigo System$134
- Ultreon$132
How this compares
$81,668 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 102 | $101,534 |
| FarxigaDapagliflozin Propanediol | 73 | $81,458 |
| JardianceEmpagliflozin | 44 | $68,254 |
| EntrestoSacubitril/Valsartan | 21 | $22,939 |
| XareltoRivaroxaban | 14 | $20,285 |
| Repatha SureclickEvolocumab | 26 | $20,255 |
| Repatha PushtronexEvolocumab | 17 | $10,246 |
| VascepaIcosapent Ethyl | 16 | $7,207 |
| Ranolazine ErRanolazine | 29 | $4,854 |
| Metoprolol Succinate | 158 | $1,937 |
| Eplerenone | 15 | $1,743 |
| Atorvastatin Calcium | 122 | $1,273 |
| Losartan Potassium | 102 | $749 |
| Spironolactone | 90 | $740 |
| Amlodipine Besylate | 127 | $714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $63 | $22,93921 claims |
| Johnson & JohnsonXarelto | $48 | $20,28514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in San Antonio
- Jorge AlvarezSan Antonio$1.6M
- Robert ChiltonSan Antonio$1.3M
- Marvin EngSan Antonio$756K
- Nandish ThukralSan Antonio$368K
- Anand PrasadSan Antonio$328K
- Jose PerezSan Antonio$312K
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.